Extended Data Fig. 5: P(G) by phase versus therapy area.
From: Refining the impact of genetic evidence on clinical success
Each panel represents one therapy area, and shows the proportion of target-indication pairs in that area with genetic support, or P(G), by development phase. The genetically supported and total number of T-I pairs at each phase in each therapy area are provided in Table S33. Total number of T-I pairs in any area: N = 10,839 preclinical, N = 4,421 phase I, N = 7,383 phase II, N = 1,551 phase III, N = 1,519 launched. The center is the exact proportion and error bars are Wilson binomial 95% confidence intervals. See Fig. S6 for the same analyses restricted to drugs with a single known target.